Tatva Chintan Pharma Chem Limited · NSE:TATVA

Tatva Chintan Pharma Chem — Q4 FY25 Earnings Presentation

38 slides from Tatva Chintan Pharma Chem's earnings presentation, May 5, 2025

  1. Slide 1: Exchange cover letter: Investor Presentation

    Date: 05 May 2025 Ref. No.: TCPCL/SEC/2025-26/00013 To, The General Manager, The Manager, Corporate relationship department, Listing department, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Fort, Bandra-Kurla Complex, Ban

  2. Slide 2: Investor Presentation Q4FY25 & FY25

    Investor Presentation Tatva Chintan Pharma Chem Limited (TCPCL) Q4FY25 & FY25 May 2025

  3. Slide 3: Contents

    Contents 01 02 03 04 Quarter & twelve-month TATVA CHINTAN at Glance Product Categories Leading Sustainable Financial Performance practices coupled with cutting edge technology 05 06 07 08 Expansive international Why TATVA CHINTAN Industry Outlook Our Business presence with Marquee clientele 2

  4. Slide 4: Consolidated Financial Performance

    Consolidated Financial Performance 3

  5. Slide 5: Q4FY25 & FY25: Financial Result highlights

    Q4FY25 & FY25: Financial Result highlights Q4FY25 HIGHLIGHTS EBIDTA (Excl. Other Income) & PAT & PAT Margin 1 (In ₹ Mn, %) EPS (In ₹) Revenue from Operations 1 (In ₹ Mn) 4.5 0 EBIDTA Margin 1 (In ₹ Mn, %) 180 18. 0% 4.0 0 160 15.9% 16. 0% 120 9.8% 11.0% 3.5 0 3.0 0 140 14. 0% 100 9.0% 2.5 0 120 12.

  6. Slide 6: Q4FY25 & FY25: Consolidated Numbers

    Q4FY25 & FY25: Consolidated Numbers Particulars (₹ Mn) Q4FY25 Q4FY24 YoY (%) Q3FY25 QoQ (%) FY25 FY24 YoY (%) Revenue from Operation 1,078.64 982.66 9.77% 858.96 25.58% 3,827.14 3,935.04 -2.74% Total Income 1,085.86 1,027.94 5.63% 859.40 26.35% 3,850.29 4,010.13 -3.99% EBITDA (Excl. Other Income) 89

  7. Slide 7: Q4FY25 & FY25: Operational highlights

    Q4FY25 & FY25: Operational highlights OPERATING REVENUE SPLIT (IN %) Q4FY25 FY25 PTC 36.0% PTC 32.8% SDA 32.1% SDA 31.3% ELECTROLYTE SALTS 0.8% ELECTROLYTE SALTS 1.6% PASC 30.3% PASC 33.6% OTHERS 0.7% OTHERS 0.7% Tatva Chintan Pharma Chem Limited 6

  8. Slide 8: Chairman & MD's Comments on Results

    Chairman & MD’s Comments on Results “ We endeavor to grow organically by incorporating innovative ideas in our operations, product development and increasing our market presence across product categories “ Mr. Chintan Shah CMD TAT V A C H I N TA N P H A R M A CHEM LIMITED • During Q4FY25, the compan

  9. Slide 9: Consolidated Financial Highlights

    Consolidated Financial Highlights REVENUE FROM OPERATIONS1 (IN ₹ MN) PROFITABILITY1 (IN ₹ MN) EBITDA (Excluding Other Income) & EBITDA Margin PAT & PAT Margin 90 57 75 23 22% 25% 14% 17% 9% 17% 22% 11% 8% 1% 52 4,336 4,236 3,935 3,827 3,004 1,082 959 304 342 682 664 57 523 606 455 FY21 FY22 FY23 FY2

  10. Slide 10: Consolidated Statement of Profit & Loss

    Consolidated Statement of Profit & Loss 31 March 2020 31 March 2021 31 March 2022 31 March 2023 31 March 2024 31 March 2025 Particulars (₹ Mn) Audited Audited Audited Audited Audited Audited Income Revenue from operations 2,632.39 3,003.59 4,336.47 4,236.12 3,935.04 3,827.14 Total Income 2,646.22 3,

  11. Slide 11: Consolidated Statement of Balance Sheet

    Consolidated Statement of Balance Sheet 31 March 2020 31 March 2021 31 March 2022 31 March 2023 31 March 2024 31 March 2025 Particulars (₹ Mn) Audited Audited Audited Audited Audited Audited Assets Fixed Assets 1,110.60 1,203.51 1,592.96 1,957.71 4,265.35 5,255.52 Capital work-in-progress 48.92 98.1

  12. Slide 12: TATVA CHINTAN at Glance

    TATVA CHINTAN at Glance 11

  13. Slide 13: TATVA CHINTAN at Glance

    TATVA CHINTAN at Glance INTEGRATED SPECIALTY CHEMICAL COMPANY, PRESENT ACROSS THE VALUE CHAIN • Established by first generation entrepreneur engineers in Manufacturing Products Revenue Split – FY25 1996 • Plants located at Ankleshwar and Dahej SEZ, Gujarat with an existing combined installed reactor

  14. Slide 14: Product Categories

    Product Categories 13

  15. Slide 15: Phase Transfer Catalyst (PTC) – a Catalyst with Innumerable Benefits

    Phase Transfer Catalyst (PTC) – a Catalyst with Innumerable Benefits WHAT ARE PTC? BENEFITS DEMAND DRIVERS • PTC are used to facilitate the • Offers faster reactions • Rising demand for technologically TATVA CHINTAN’S migration of a reactant from one • Higher conversion/yields, advanced environment-

  16. Slide 16: Structure Directing Agents (SDA)

    Structure Directing Agents (SDA) – an important ingredient for making the world more sustainable WHAT ARE SDA? BENEFITS DEMAND DRIVERS • High purity Quaternary salts that SDAs are important raw material for • With the recent developments in TATVA CHINTAN’S helps in the formation of creation of high

  17. Slide 17: Electrolysis – a better and greener way of producing SDAs

    Electrolysis – a better and greener way of producing SDAs ABOUT ELECTROLYSIS BENEFITS • TATVA started R&D into developing SDAs • Electrolysis is considered as a ‘green’ since 2007 chemistry process wherein apart from a single starting raw material, the process largely uses • In 2015, it received com

  18. Slide 18: Electrolyte Salts – aiding the technological thrust

    Electrolyte Salts – aiding the technological thrust WHAT ARE ELECTROLYTE BENEFITS DEMAND DRIVERS • Due to their properties like fast TATVA CHINTAN’S SALTS? Currently, these are used along with charging ability, superior low Lithium battery in EV vehicles PRESENCE IN SALTS • Electrolyte Salts are use

  19. Slide 19: Pharmaceuticals and Agrochemicals Intermediates and other Specialty Chemicals (PASC)

    Pharmaceuticals and Agrochemicals Intermediates and other Specialty Chemicals (PASC) – WHICH PRODUCTS ARE END USER INDUSTRY TATVA CHINTAN’S TATVA is the largest MANUFACTURED? APPLICATION POSITION IN PASC producer of Glymes in India and third • Various pharmaceutical and agrochemical products such as

  20. Slide 20: Continuous Flow Chemistry – sophisticated method with analytical expertise

    Continuous Flow Chemistry – sophisticated method with analytical expertise ABOUT BENEFITS PROCESS • TATVA CHINTAN started R&D into • Continuous Flow Chemistry is • Structure directing agents are continuous flow chemistry since considered as a ‘green’ chemistry converted to Zeolite based catalysts 20

  21. Slide 21: Value derived from Product Categories

    Value derived from Product Categories REVENUE FROM EACH PRODUCT CATEGORY1 (In ₹ Mn.) 2,248 Considering the wide range of applications of our products, Tatva Chintan can cater to 1,655 customers across wide spectrum of Chemical Industries which ensures a 1,432 1,335 1,287 1,277 sustainable business m

  22. Slide 22: Leading Sustainable practices coupled with cutting edge technology

    Leading Sustainable practices coupled with cutting edge technology 21

  23. Slide 23: Integrated and Modern Manufacturing Facility

    Integrated and Modern Manufacturing Facility ANKLESHWAR DAHEJ SEZ • Both the plants are in-close proximity to • Manufacturing facility started in 1996 • Manufacturing started in 2017 Hazira port. • Converted into a ‘zero liquid effluent discharge’ facility from • Company has having sophisticated qua

  24. Slide 24: One of the prominent Research & Development center

    One of the prominent Research & Development center R&D CAPITAL AND REVENUE EXPENDITURE • Dedicated R&D facility at Vadodara recognized by the Department of (In ₹ Mn.) 300 .00 Scientific and Industrial Research (“DSIR”), Government of India. • Equipped with glass assemblies, continuous flow reactors,

  25. Slide 25: …With a focus on 'green' chemistry processes

    …With a focus on ‘green’ chemistry processes Tatva Chintan’s ‘green’ chemistry is based on the principles of clean chemistry, minimum requirement of auxiliary substances, minimum waste and by-products and safe chemistry • Undertaking various ‘green’ chemistry processes • By deploying electrolysis fo

  26. Slide 26: Expansive international presence with Marquee clientele

    Expansive international presence with Marquee clientele 25

  27. Slide 27: Fostered long term relationship with marquee clientele

    Fostered long term relationship with marquee clientele while continuously expanding presence in global market ESTEEMED CUSTOMERS EXPORTS • Tatva exports products to over 25+ countries viz. USA, China, Germany, Japan, South Africa and UK. • Subsidiaries facilitates overseas operations:- • Tatva Chint

  28. Slide 28: Why TATVA CHINTAN

    Why TATVA CHINTAN 27

  29. Slide 29: Investment Rationale

    Investment Rationale Presence in niche Track record of Wide basket of Continuous focus High industry Capex to boost the specialty chemicals developing wide products are used in on R&D and in house barriers as new capacities and pave space with limited product basket varied industries developed entra

  30. Slide 30: Industry Outlook

    Industry Outlook 29

  31. Slide 31: India's rapidly expanding footprint in Global Chemical Market

    India's rapidly expanding footprint in Global Chemical Market SHARE OF COUNTRIES IN GLOBAL TRENDS IN SPECIALTY CHEMICALS LANDSCAPE CHEMICAL INDUSTRY (IN %) Indian Chemical Move towards Opportunity Industry got sustainable product for Indian Advantage vs development: Manufacturers: CHINA 39% China du

  32. Slide 32: Global Chemical Industry market size

    Global Chemical Industry GLOBAL PTC SDA CHEMICAL Commodity Chemicals INDUSTRY • Basic Chemicals 1,190 1.19 MARKET SIZE • Manufactured In large volumes Mkt Size 2022 (USD Mn) Mkt Size 2022 (USD bn) • Mkt Size USD 3,700bn • ~Expected 4% CAGR 1,640 5.5% 1.65 5.6% 5,030 Speciality Chemicals Mkt Size 202

  33. Slide 33: Our Business

    Our Business 32

  34. Slide 34: Major Events & Milestones

    Major Events & Milestones 1996 2007 2013 2017 2019 2021 Incorporation of our Expansion of Achieved turnover Set up our Dahej SEZ Incorporation of • Listed on Company manufacturing capacity at of ₹ 500.00 million Manufacturing Facility Tatva Chintan Europe BSE and NSE our Ankleshwar BV, a wholly owne

  35. Slide 35: Leadership and Management

    Leadership and Management Chintan Nitinkumar Ajaykumar Shekhar Rasiklal Dr. Manher Chimanlal CA Subhash Dr. Avani Rajesh Shah Mansukhlal Patel Somani Desai Ambubhai Patel Umatt M ANA G I N G D I R E C T O R WHOLE TIME DIRECTOR WHOLE TIME DIRECTOR I ND E P E ND E NT D I R E C T O R I ND E P E ND E NT

  36. Slide 36: Shareholder Information

    Shareholder Information SHAREHOLDING PATTERN- March 2025 (IN %) NSE Ticker TATVA BSE Ticker 543321 IPO Listing Date 29 July 2021 Share Price (₹)^ 677 PROMOTER 72.02% Market Cap (₹ Mn)^ 15,840 MF 5.34% % Free Float^ 27.98% March PUBLIC 18.66% Free float market cap (₹ Mn)^ 4,432 2025 FPI 3.30% Shares

  37. Slide 37: Safe Harbor

    Safe Harbor Certain statements in this presentation concerning our future growth prospects are forward looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company's results may

  38. Slide 38: Thank You

    May 2025 Thank You TATVA CHINTAN PHARMA CHEM LIMITED INVESTOR RELATIONS AT CORPORATE OFFICE TATVA CHINTAN Plot No. 353, G.I.D.C, Mr. Ashok Bothra Makarpura, Vadodara – 390 010, Gujarat, India finance@tatvachintan.com BSE: 543321 EY NSE: TATVA Ms. Krishna Patel | Mr. Arpit Mundra CIN: L24232GJ1996PLC

Tatva Chintan Pharma Chem — Q4 FY25 Earnings Presentation on 6ix